AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical development

SINGAPORE, Jan. 15, 2025 /PRNewswire/ — Axcynsis Therapeutics Pte Ltd (“Axcynsis”), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly announces the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors. Axcynsis is planning to initiate a Phase 1 multicentre clinical trial in the United States in 1Q 2025.

AT03-65 is a differentiated ADC that selectively binds to CLDN6 with strong affinity. It is enabled by AxcynDOT™, a proprietary payload that incorporates a derivative of an approved oncology therapeutics with unique mechanism of action and broad anti-tumor activity, and coupled with a cleavable and hydrophilic proprietary linker. CLDN6 is overexpressed in many cancers including lung, ovarian, endometrial, uterine, testicular, and gastric cancers while exhibiting minimal expression in normal tissues.  AT03-65 is designed to deliver targeted therapy to improve patient outcomes with advanced or metastatic CLDN6-positive cancers.

“This is a transformational event for Axcynsis and a significant milestone for our proprietary ADC platform using AxcynDOT™,” said Dr. Zou Bin, CEO of Axcynsis. “We are pleased that FDA has cleared AT03-65 which leverages our AxcynDOT™ technology for this first-in-human study.  We are very excited with the potential of offering a transformative therapeutic option for patients with CLDN6-positive tumors as well as advancing our pipeline with  differentiated  and effective ADCs using AxcynDOT™ to improve the lives of cancer patients worldwide”.

The upcoming Phase 1 multicentre clinical trial in the United States will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AT03-65 in patients with advanced CLDN6-positive solid tumors.

About AT03-65

AT03-65 is a recombinant anti-CLDN6 monoclonal antibody conjugated to AxcynDOT™, a proprietary payload developed by Axcynsis with a differentiated mechanism of action and broad anti-cancer activities.  AT03-65 is designed to target advanced, recurrent, or metastatic CLDN6+ solid tumors in patients who have progressed on or after standard systemic treatment or for whom no standard therapies are available.

The antibody of AT03-65 is rationally engineered for high affinity and specificity to CLDN6. Upon binding to CLDN6-expressing tumor cells, the ADC is internalized into lysosomes, where it releases its payload to inhibit tumor growth effectively. Preclinical studies demonstrate that AT03-65 not only directly kill CLDN6-positive tumor cells but also exhibits bystander killing effect, targeting neighboring CLDN6-negative tumor cells to enhance its anti-tumor efficacy. AT03-65 has demonstrated promising anti-tumor activities in multiple tumor mouse models and a favorable safety profile in non-human primates.

About AxcynDOT™

This is a proprietary payload developed by Axcynsis. It is a derivative of trabectedin, an approved chemotherapy in the United States, Europe and selected Asian countries, with a unique mechanism of action that is differentiated from other DNA alkylating payloads. AxcynDOT™ is optimized with enhanced potency and improved safety profile compared to trabectedin.

About Axcynsis Therapeutics

Axcynsis Therapeutics is a pioneering biotechnology company headquartered in Singapore with operations in the United States. The company has developed AxcynDOT™ , a proprietary linker payload platform to advance a pipeline of differentiated ADC candidates aimed at addressing key unmet medical needs. The company is committed to advance effective and targeted oncology therapeutics with breakthrough potential to improve the lives of cancer patients worldwide.

For more information, please visit Axcynsis Therapeutics’ official website
https://axcynsis.com/

Contact Information

Axcynsis Therapeutics Pte Ltd
41 Science Park Road
#04-18, The Gemini
Singapore 117610
Email: contactus@axcynsis.com

BENGALURU, India, Jan. 15, 2025 /PRNewswire/ — 6D Technologies, a global leader in digital transformation solutions, proudly announces the successful migration of M1 Limited’s Prepaid and Maxx services to the 6D Technologies Canvas, a cutting-edge Digital BSS platform. Over 15 months, 6D Technologies migrated all of M1’s Prepaid and Maxx (Postpaid) subscribers from legacy systems to Canvas. This modernization enhanced service delivery, operational efficiency, and customer experience with minimal disruption, marking a significant milestone in M1’s digital evolution.

The migration project leveraged the comprehensive suite of licensed software modules offered by 6D Technologies. These modules form a holistic ecosystem that streamlines operations:

• Canvas includes advanced Customer Relationship Management, a Unified Product Catalogue, Order and Workflow Management, Billing and Invoicing, Billing Mediation, 6D Technologies Digital API Gateway, 6D Technologies ESB, Notification Engine, Reporting, and Single Sign-On (SSO).
• Magik, the Campaign Management Solution, offers a Business Rule Engine, Advanced Analytics, Loyalty Management, Data Management Capability, BI and Reporting, and Commissioning for Retailers.
• Aureus features a Retailer Portal for seamless E-top-up services.
• Other integral modules include a SIM and Number Management System, Web Self-Care, Gamification with five interactive games, and a robust Voucher Management System.

Marko Cetkovic, Chief Digital Officer at M1, added, “Our partnership with 6D Technologies is key to modernizing Digital BSS and Campaign Management. Migrating our legacy Prepaid and Maxx customer base to the new platform drives operational efficiencies and reduces time to market, aligning with our strategy to future-proof our operations.”

Manish Arora, Co-Founder and CRO of 6D Technologies, stated, “The successful migration of M1’s Prepaid and Maxx services to our Canvas platform underscores the power and scalability of our Digital BSS solutions. This migration not only enhances operational efficiency but also empowers M1 to deliver superior, data-driven customer experiences. We remain committed to helping our clients excel in a competitive telecom landscape.”

About 6D Technologies

6D Technologies provides innovative digital transformation solutions for CSPs. Its scalable platforms empower telecom operators to streamline operations, enhance customer experiences, and drive growth, redefining business management in an ever-evolving digital ecosystem.

SYDNEY, Jan. 15, 2025 /PRNewswire/ —
Leading European sauna brand Auroom and SDS Australia have announced an exclusive partnership

Brazil Takes Center Stage as Partner Country in a Growing Edition with 9,500 Companies from 156 Countries and 884 Main Exhibitors

MADRID, Jan. 15, 2025 /PRNewswire/ — Organized by IFEMA MADRID, the International Tourism Trade Fair (FITUR) will bring together the global tourism market for its 45th edition, running from January 22 to 26. The event will highlight the exceptional performance of the tourism industry in 2024 and its promising outlook for 2025. A context of strength in which the industry, united under FITUR, seeks to highlight its pride in belonging to the sector, its transformative role, and its commitment to sustainability and innovation.

FITUR once again opens the international calendar of tourism fairs, reaffirming its leadership as the top event by volume of participants and attendees, with the backing of all public and private stakeholders in the value chain. This is supported by the figures presented during the press conference: 9,500 participating companies, 156 countries, and 884 main exhibitors showcasing their offerings across nine halls, including 101 countries with official representation.

Additionally, the excellent industry response to FITUR 2025 is expected to be reflected in attendance numbers, with projections exceeding 150,000 professionals from Wednesday to Friday and around 100,000 general public visitors over the weekend. This influx is estimated to generate an economic impact of €445 million for Madrid, positively affecting sectors such as transportation, hotels, gastronomy, culture, and entertainment.

FITUR: A Key Global Gathering for the Tourism Industry

After a year of post-pandemic recovery in 2024, FITUR is once again defined by growth. The direct participation of main exhibitors has reached 884, marking a 10% overall increase and a 19% rise in international representation.

This international focus, central to FITUR’s objectives, is reflected in the 101 official country representations—five more than in the previous edition—and the addition of eleven new countries joining FITUR 2025, primarily from Africa and Asia.

Highlighting the role of innovation, the Travel Technology area has grown by 6%, showcasing global trends in tourism booking technologies and featuring over 100 companies worldwide.

Among the highlights for 2025 is Brazil’s participation as Partner Country, with a significant presence to showcase its diverse tourism offerings and strengthen its global positioning. According to data from Brazil’s Ministry of Tourism and Embratur, 2024 was a record year for international tourism, with 6,657,377 foreign visitors, a 12.6% increase from the previous year.

The Future of Tourism: Business, Knowledge, and Sustainability

FITUR has renewed its ten thematic sections, emphasizing sustainability and business by connecting the tourism industry with other sectors to generate new traveler niches.

FITUR Cruises, developed with CRUCEROADICTO, will highlight the cruise industry’s commitment to sustainability. FITUR LGTB+ will promote diversity and inclusion, while FITUR Lingua will explore language tourism opportunities in partnership with FEDELE. FITUR Screen, in collaboration with the SPAIN FILM COMMISSION, will connect the film and tourism industries. Meanwhile, FITUR Sports, in partnership with AFYDAD, will demonstrate how sports tourism fosters responsible tourism.

FITUR Techy, created with ITH, will explore how AI is revolutionizing travel management. FITUR Talent will focus on challenges in talent and training. FITUR Woman, in collaboration with WOMEN LEADING TOURISM, will promote female leadership. FITUR Know How & Export, developed with SEGITTUR in partnership with ICEX, will showcase the potential of Spanish tourism companies. Lastly, FITUR 4all, in collaboration with IMPULSA IGUALDAD, will advance accessible tourism through initiatives such as the second FITUR 4all Awards and the first Best Practices Guide.

The Sustainability Observatory, FITURNEXT will address how tourism can contribute to sustainable food management.

More information on https://www.ifema.es/en/fitur.

SYDNEY, Jan. 15, 2025 /PRNewswire/ — Busways, the largest Australian-owned bus operator, has appointed Will O’Neill as its new Chief Executive Officer, effective January 1, 2025.

Mr O’Neill steps up to the helm after a decade of strong leadership at Busways, most recently as Chief Financial Officer and Commercial Officer, and with 30 years’ commercial and financial experience.

He succeeds Byron Rowe, grandson of founder Dick Rowe, who moves to Executive Chair of the Busways Board after seven transformative years as Managing Director of the 82-year-old company.  Under Mr Rowe’s leadership, Busways doubled in size, solidifying its position as the largest Australian-owned bus operator, successfully navigating expansions and challenging times.

Mr Rowe explains that the shift ensures Busways is primed for long-term success.

“This transition is all about strengthening Busways and setting us up for what’s next. We’ve got a strong team at Busways and a clear plan in place,” Mr Rowe says.

“As Executive Chair, I will concentrate on strategic projects and long-term growth initiatives, ensuring we continue to deliver exceptional service and value for government and communities.”

“Having worked alongside Will for over a decade, I’m fully confident in his ability to lead Busways with the same dedication and drive we’ve always shared,” he says.

“His commitment and insight make him a natural fit for the role, he’ll keep our dedicated team moving forward with strength and purpose.”

Mr O’Neill says he looks forward to focusing on leading the business and preparing Busways for growth opportunities.

“At the heart of my new responsibility as CEO is doing justice to the legacy that has been built in this business, together with guiding our continued development and growth to set up for the next generation of leaders” Mr O’Neill said.

A key part of that is developing and retaining good people, he says.

“As a service business, our people are the key to our success.  We work hard to provide our people with the environment they need to succeed. This is a great business, with great people.”

“This is why Busways is an Australian success story.  In the 1970’s there were approximately 40 private bus operators in the Sydney metro area, the most challenging and competitive market in Australia.  Today, there is only one – Busways – and we serve 20% of the market.

“I am truly grateful for the opportunity to lead such a wonderful organisation and I am excited about continuing to deliver for our clients and customers as we continue to grow.”

Will O’Neill brings over 30 years of expertise in senior executive leadership, corporate finance, and strategic planning, including leadership roles at KPMG and other advisory firms. He has led or advised on complex, high-impact projects, advising governments and corporations in a range of industries.

This leadership change marks a natural progression in Busways’ journey as the company continues to expand its footprint and lead innovation in public transport services.

Contact Busways Media team at media@busways.com.au

ONTARIO, Calif., Jan. 15, 2025 /PRNewswire/ — Nature’s Miracle Holding Inc. (NASDAQ: NMHI) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology and infrastructure, today announced that on January 13, 2025, the Company received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s common stock and warrants from Nasdaq due to the Company’s failure to comply with minimum shareholder’s equity requirement under Nasdaq Listing Rule 5550(b)(1). The Notice indicated that trading in the Company’s common stock and warrants will be suspended on Nasdaq, effective at the open of business on January 15, 2025.

The Company has 15 days after the date it received notice of the Panel’s decision to request that the Nasdaq Listing and Hearing Review Council (the “Council”) review the Hearing Panel’s decision, or the Council may, on its own motion, determine to review the Hearing Panel’s decision within 45 calendar days of the issuance of  the decision.

The Company is considering to appeal the decision.

Upon suspension of the trading of its common stock on Nasdaq, the Company expects that its common stock and warrants will be quoted under its existing symbol “NMHI” and “NMHW” respectively, on the OTC Pink .

About Nature’s Miracle Holding Inc.

Nature’s Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing products and services to growers in the Controlled Environment Agriculture (“CEA”) industry around the world. The company has recently launched EV and bitcoin business, all energy dependent as CEA.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of Nature’s Miracle’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in Nature’s Miracle’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; Nature’s Miracle’s ability to develop and launch new products and services; Nature’s Miracle’s ability to successfully and efficiently integrate future expansion plans and opportunities; Nature’s Miracle’s ability to grow its business in a cost-effective manner; Nature’s Miracle’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of Nature’s Miracle’s business model; developments and projections relating to Nature’s Miracle’s competitors and industry; and Nature’s Miracle’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; the effects of the coronavirus (COVID-19) and any future outbreaks on Nature’s Miracle’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nature’s Miracle’s operates; the risk that Nature’s Miracle’s and its current and future collaborators are unable to successfully develop and commercialize Nature’s Miracle’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that Nature’s Miracle’s is unable to secure or protect its intellectual property; the possibility that Nature’s Miracle’s may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in Nature’s Miracle’s filings from time to time with the SEC.

For more information, please contact:

Nature’s Miracle Holding, Inc.
Investor Relations Department
ir@nature-miracle.com

Ascent Investors Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Dr. Bor Jang Showcases Graphene’s Transformative Potential for Next-Generation Energy Storage Solutions

DAYTON, Ohio, Jan. 15, 2025 /PRNewswire/ — Solidion Technology, Inc. (NASDAQ: STI), an advanced battery technology solutions provider, proudly announces that Dr. Bor Jang, the company’s Board Chairman and Chief Science Officer, delivered the keynote address at the Innovative & Industrial 2D/Advanced Materials Summit & Expo (I2DM2024) in Abu Dhabi, UAE.

The I2DM Summit convenes the world’s foremost researchers, industry leaders, and visionaries to explore and unlock the boundless potential of Advanced Materials, including graphene, a two-dimensional (2D) wonder material. Dr. Jang, a pioneering figure in graphene innovation, shared insights on its transformative applications in energy storage and battery technologies.

Dr. Jang’s credentials are unparalleled in the field of materials science. A graduate of MIT with MS and PhD degrees, he has held prestigious roles, including Dean of the College of Engineering and Computer Science and Professor at Wright State University. His remarkable achievements include:

• Discovery of Graphene (2002): Dr. Jang filed the world’s first patent application on graphene.
• Breakthrough Inventions: His team pioneered graphene supercapacitors (2006) and graphene-enabled batteries (2007).
• Prolific Innovator: Co-inventor of over 680 U.S. patents and 200+ international patents (issued and pending).
• Recognition as a National Academy of Inventors Fellow (2019): Honoring his contributions to innovation.

Dr. Jang’s keynote addressed the transformative role of graphene in energy storage, emphasizing its applications in anodes, cathodes, and current collectors for next-generation batteries, including:

• Lithium-ion and sodium-ion batteries for electric vehicles (EVs) and consumer electronics.
• Lithium-metal and lithium-sulfur batteries offering higher energy density and improved safety.
• Aluminum-ion batteries, an emerging solution for sustainable energy storage.

Dr. Jang demonstrated how graphene’s superior conductivity, lightweight properties, and mechanical strength enable batteries to achieve higher energy density, longer lifespans, and faster charging capabilities—critical advancements to meet the growing demand for efficient and sustainable energy solutions.

For more information, please visit www.solidiontech.com or contact Investor Relations.

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion’s (NASDAQ: STI) core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. Solidion holds a portfolio of over 550 patents, covering innovations such as high-capacity, non-silane gas and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies. Headquartered in Dallas, Texas with R&D and production facilities in Dayton, Ohio, Solidion’s core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation.

Cautionary Note Regarding Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Boudewijn Pesch Joins Verkada as Vice President of JAPAC Channel Sales

SAN MATEO, Calif., Jan. 15, 2025 /PRNewswire/ — Verkada,
Boudewijn Pesch, Vice President of Japan and Asia-Pacific Channel Sales at Verkada